QQQ   444.36 (-0.11%)
AAPL   171.00 (-1.33%)
MSFT   420.15 (-0.30%)
META   486.36 (-1.52%)
GOOGL   150.47 (-0.27%)
AMZN   180.21 (+0.21%)
TSLA   176.37 (-1.92%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.35 (+0.98%)
BABA   72.42 (+1.16%)
T   17.58 (+0.17%)
F   13.29 (+1.76%)
MU   118.04 (-0.92%)
CGC   9.95 (+4.19%)
GE   175.47 (-2.58%)
DIS   122.88 (+1.57%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.12 (+0.83%)
XOM   115.74 (+0.67%)
QQQ   444.36 (-0.11%)
AAPL   171.00 (-1.33%)
MSFT   420.15 (-0.30%)
META   486.36 (-1.52%)
GOOGL   150.47 (-0.27%)
AMZN   180.21 (+0.21%)
TSLA   176.37 (-1.92%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.35 (+0.98%)
BABA   72.42 (+1.16%)
T   17.58 (+0.17%)
F   13.29 (+1.76%)
MU   118.04 (-0.92%)
CGC   9.95 (+4.19%)
GE   175.47 (-2.58%)
DIS   122.88 (+1.57%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.12 (+0.83%)
XOM   115.74 (+0.67%)
QQQ   444.36 (-0.11%)
AAPL   171.00 (-1.33%)
MSFT   420.15 (-0.30%)
META   486.36 (-1.52%)
GOOGL   150.47 (-0.27%)
AMZN   180.21 (+0.21%)
TSLA   176.37 (-1.92%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.35 (+0.98%)
BABA   72.42 (+1.16%)
T   17.58 (+0.17%)
F   13.29 (+1.76%)
MU   118.04 (-0.92%)
CGC   9.95 (+4.19%)
GE   175.47 (-2.58%)
DIS   122.88 (+1.57%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.12 (+0.83%)
XOM   115.74 (+0.67%)
QQQ   444.36 (-0.11%)
AAPL   171.00 (-1.33%)
MSFT   420.15 (-0.30%)
META   486.36 (-1.52%)
GOOGL   150.47 (-0.27%)
AMZN   180.21 (+0.21%)
TSLA   176.37 (-1.92%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.35 (+0.98%)
BABA   72.42 (+1.16%)
T   17.58 (+0.17%)
F   13.29 (+1.76%)
MU   118.04 (-0.92%)
CGC   9.95 (+4.19%)
GE   175.47 (-2.58%)
DIS   122.88 (+1.57%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   67.12 (+0.83%)
XOM   115.74 (+0.67%)
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

$0.57
-0.03 (-4.50%)
(As of 12:09 PM ET)
Today's Range
$0.56
$0.60
50-Day Range
$0.28
$0.66
52-Week Range
$0.13
$3.46
Volume
286,566 shs
Average Volume
956,111 shs
Market Capitalization
$28.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Brainstorm Cell Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,594.3% Upside
$10.00 Price Target
Short Interest
Healthy
1.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.78mentions of Brainstorm Cell Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.70) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.34 out of 5 stars

Medical Sector

190th out of 939 stocks

Biological Products, Except Diagnostic Industry

24th out of 156 stocks

BCLI stock logo

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BCLI Stock Price History

BCLI Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
BCLI Mar 2024 1.500 call
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc (BCLI)
Brainstorm Cell Therapeutics Inc. (BCLI)
BCLI Brainstorm Cell Therapeutics Inc.
BrainStorm Issues 2023 Letter to Shareholders
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BCLI
Fax
N/A
Employees
42
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+1,630.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.08) per share

Miscellaneous

Free Float
46,312,000
Market Cap
$28.31 million
Optionable
Optionable
Beta
0.22
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Chaim Lebovits (Age 53)
    President & CEO
    Comp: $990.42k
  • Dr. Stacy R. Lindborg Ph.D. (Age 54)
    Co-Chief Executive Officer
    Comp: $708.39k
  • Dr. Irit Arbel DSc (Age 64)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Mr. Uri Yablonka (Age 47)
    Executive VP, Chief Business Officer, Secretary & Director
  • Ms. Alla Patlis CPA (Age 37)
    M.B.A., Controller & Interim CFO
    Comp: $80k
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor
  • Ms. Mary Kay Turner
    Senior Vice President of Patient Advocacy & Government Affairs
  • Dr. Ibrahim Dagher M.D. (Age 55)
    Executive VP & Chief Development Officer

BCLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings
or view top-rated stocks.

What is Brainstorm Cell Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Brainstorm Cell Therapeutics' stock. Their BCLI share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 1,594.3% from the stock's current price.
View analysts price targets for BCLI
or view top-rated stocks among Wall Street analysts.

How have BCLI shares performed in 2024?

Brainstorm Cell Therapeutics' stock was trading at $0.2730 on January 1st, 2024. Since then, BCLI stock has increased by 116.2% and is now trading at $0.5902.
View the best growth stocks for 2024 here
.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 850,300 shares, a drop of 20.5% from the February 29th total of 1,070,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is presently 0.6 days.
View Brainstorm Cell Therapeutics' Short Interest
.

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BCLI earnings forecast
.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). During the same quarter in the previous year, the company posted ($0.19) earnings per share.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include ADAR1 Capital Management LLC (0.00%), Barclays PLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCLI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners